Evidence map›Paper›PMID 28739897›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2017

Antibacterial photosensitization through activation of coproporphyrinogen oxidase.

Matthew C Surdel, Dennis J Horvath, Lisa J Lojek, Audra R Fullen, Jocelyn Simpson, Brendan F Dutter, Kenneth J Salleng, Jeremy B Ford, J Logan Jenkins, Raju Nagarajan and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Structural aspects of enzymes involved in prokaryotic Gram-positive heme biosynthesis.Computational and structural biotechnology journal · 2023
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Nonconventional Therapeutics againstMicrobiology spectrum · 2018
    Article
  16. Review
  17. mBio · 2018
    Article
  18. Transcriptional Response ofFrontiers in microbiology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Matthew C SurdelDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.
Dennis J HorvathDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.
Lisa J LojekDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.
Audra R FullenDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.
Jocelyn SimpsonDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.
Brendan F DutterDepartment of Chemistry, Vanderbilt University, Nashville, TN 37232.
Kenneth J SallengDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.
Jeremy B FordDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN 37232.
J Logan JenkinsDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN 37232.
Raju NagarajanVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232.
Pedro L TeixeiraBiomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN 37203.
Matthew AlbertolleVanderbilt Institute for Chemical Biology, Nashville, TN 37232.
Ivelin S GeorgievDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.
E Duco JansenDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN 37232.
Gary A SulikowskiDepartment of Chemistry, Vanderbilt University, Nashville, TN 37232.
D Borden LacyDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232.
Harry A DaileyBiomedical and Health Sciences Institute, University of Georgia, Athens, GA 30602.
Eric P SkaarDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232; eric.skaar@vanderbilt.edu.
Vanderbilt University Medical Center · USVanderbilt University · USUniversity of Georgia · US

Funding

Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
TRAINING PROGRAM IN ENVIRONMENTAL TOXICOLOGYT32ES007028 · NIEHS · VANDERBILT UNIVERSITY · PI F PETER Guengerich, Fiona Edith Harrison · 1985 to 2026
$15.7M
TRAINING PROGRAM IN CELLULAR, BIOCHEMICAL, &MOLECULAR ST32GM008554 · NIGMS · VANDERBILT UNIVERSITY · PI PATTON, JAMES G. · 1995 to 2020
$7.4M
Chemistry-Biology Interface Training GrantT32GM065086 · NIGMS · VANDERBILT UNIVERSITY · PI BACHMANN, BRIAN O, SULIKOWSKI, GARY ALLEN · 2002 to 2022
$7.0M
From GWAS to PheWAS: Scanning the EMR Phenome for Gene-disease AssociationsR01LM010685 · NLM · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BASTARACHE, LISA · 2011 to 2022
$6.3M
Pathobiology of heme inducible transporters in Gram positive pathogensR01AI073843 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SKAAR, ERIC P · 2009 to 2025
$5.9M
Mechanism and function of heme-iron utilization in staphylococcal pathogenesisR01AI069233 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SKAAR, ERIC P · 2006 to 2020
$5.6M
NIAID NIH HHS R01 AI069233NIAID NIH HHS R01 AI073843NIDDK NIH HHS P30 DK058404NIEHS NIH HHS T32 ES007028NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM008554NIGMS NIH HHS T32 GM065086NLM NIH HHS R01 LM010685
6 · The paper itself

Abstract

Gram-positive bacteria cause the majority of skin and soft tissue infections (SSTIs), resulting in the most common reason for clinic visits in the United States. Recently, it was discovered that Gram-positive pathogens use a unique heme biosynthesis pathway, which implicates this pathway as a target for development of antibacterial therapies. We report here the identification of a small-molecule activator of coproporphyrinogen oxidase (CgoX) from Gram-positive bacteria, an enzyme essential for heme biosynthesis. Activation of CgoX induces accumulation of coproporphyrin III and leads to photosensitization of Gram-positive pathogens. In combination with light, CgoX activation reduces bacterial burden in murine models of SSTI. Thus, small-molecule activation of CgoX represents an effective strategy for the development of light-based antimicrobial therapies.

Indexed as

PhototherapyAnimalsBacterial ProteinsCoproporphyrinogen OxidaseCoproporphyrinsDisease Models, AnimalMicePhotosensitizing AgentsStaphylococcal Skin InfectionsStaphylococcus aureusBacterial Proteinscoproporphyrin IIICoproporphyrinogen OxidaseCoproporphyrinsPhotosensitizing AgentsantibioticbacteriaCgoXhemephotosensitization

Identifiers

PMID28739897
PMCPMC5559000
OpenAlexW2740787487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.